# An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours

> **NCT04440956** · EARLY_PHASE1 · COMPLETED · sponsor: **Clarity Pharmaceuticals Ltd** · enrollment: 10 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** 64Cu-SARTATE

## Key facts

- **NCT ID:** NCT04440956
- **Lead sponsor:** Clarity Pharmaceuticals Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-21
- **Primary completion:** 2016-02-25
- **Final completion:** 2016-02-25
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04440956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04440956, "An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04440956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*